With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Cancer Susceptibility and Signaling Pathways in Low-Grade Brain Tumors||Jewish General Hospital / Bárbara Rivera, PhD||Young Investigator Grants||2017||Quebec|
|Development of Novel Biomarkers for Immunotherapy in Neuroblastoma||Columbia Institute for Cancer Genetics / Shuobo Boboila, PhD||Young Investigator Grants||2017||New York|
|A leukemia organoid platform for dissection and targeting of tumor-niche interactions||Columbia Institute for Cancer Genetics / Adolfo Ferrando, MD/PhD||Innovation Grants||2021||New York|
|Cell Line and Xenograft Repository||Texas Tech University Health Sciences Center / Patrick Reynolds, MD/PhD||Catalyst Grants||2014||Texas|
|Restoring RUNX1 Levels in FPD/AML||University of Washington, Seattle / Marshall Horwitz, MD/PhD||Familial RUNX1 Research Grants||2016||Washington|
|Delivering on the Promise of Germline Genetic Testing for RUNX1 Variants||University of Washington, Seattle / Abbye McEwen, MD, PhD||RUNX1 Early Career Investigator Grants||2022||Washington|
|Identifying Therapeutic Targets to Prevent Progression of Familial RUNX1 Disorder to AML Using Novel iPSC Models||Icahn School of Medicine at Mount Sinai / Eirini Papapetrou, MD/PhD||Familial RUNX1 Research Grants||2016||New York|
|Modeling the Initiation and Progression of Down Syndrome Associated Leukemia Using CRISPR/Cas9 at Single Cell Resolution||Icahn School of Medicine at Mount Sinai / Elvin Wagenblast, PhD||Young Investigator Grants||2020||New York|
|IND-Enabling Studies for WNTinib, a Novel Selective Therapeutic for CTNNB1 Mutant Hepatoblastomas||Icahn School of Medicine at Mount Sinai / Ernesto Guccione, PhD & Josep Llovet, MD & Arvin Dar, PhD||Reach Grants||2021||New York|
|Developing Novel Transcription Factor PROTACs to Disrupt the HMGA1 Epigenome in Relapsed Leukemia||Icahn School of Medicine at Mount Sinai / Linda Resar, MD and Jian Jin, PhD||Innovation Grants||2022||New York|